Vladimir Kadinov

Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study

Won Park, Dae‐Hyun Yoo, Pedro C. Miranda et al. · Annals of the Rheumatic Diseases · 2016 · 229 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +13

A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study

Dae‐Hyun Yoo, Artur Racewicz, Jan Brzezicki et al. · Arthritis Research & Therapy · 2016 · 171 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study

Won Park, Dae‐Hyun Yoo, Janusz Jaworski et al. · Arthritis Research & Therapy · 2016 · 139 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +9

OP0068 A Phase 3 Randomised Controlled Trial to Compare CT-P13 with Infliximab in Patients with Active Rheumatoid Arthritis: 54 Week Results from the Planetra Study

Dae‐Hyun Yoo, Artur Racewicz, Jan Brzezicki et al. · Annals of the Rheumatic Diseases · 2013 · 28 citations

Medicine, Clinical Sciences, Pharmacotherapy +12

FRI0421 A randomised, double-blind, parallel-group, phase 1 study comparing the pharmacokinetics, safety and efficacy of ct-p13 and infliximab in patients with active ankylosing spondylitis: 54 week results from the planetas study

W. Park, Janusz Jaworski, Jan Brzezicki et al. · Annals of the Rheumatic Diseases · 2013 · 24 citations

Medicine, Pharmacology, Pharmacotherapy +11